Question · asked by 1 review
Rufinamide plus ASMs vs other ASM plus ASMs: Number of participants with ≥ 75% reduction in all seizures
- Population
- Lennox‐Gastaut syndrome, any age
- Intervention
- Rufinamide plus ASMs
- Comparison
- other ASM plus ASMs
- Outcome
- Number of participants with ≥ 75% reduction in all seizures
The review found no eligible studies for this question.
What each review found
Include earlier review versions| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Rufinamide plus ASMs vs other ASM plus ASMs Number of participants with ≥ 75% reduction in all seizures · Lennox‐Gastaut syndrome, any age The review found no eligible studies for this question. Anti‐seizure medications for Lennox‐Gastaut syndrome (2021) · Cochrane Headline outcomes only | no estimate extracted | Not reported | No studies found |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Anti‐seizure medications for Lennox‐Gastaut syndrome 2021 · Cochrane Headline outcomes only | Not reported | Not extracted | Not assessed |
Related questions
The same intervention and outcome, asked in another population or against another comparator.
- Rufinamide plus ASMs vs placebo plus ASMs · Lennox‐Gastaut syndrome, any age · 1 review
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.